









Markets
/
Stocks
/
nasdaq-tbph
/

Theravance Biopharma Inc

TBPH

20.480USD

+0.900+4.60%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

1.04BMarket Cap

35.32P/E TTM



Theravance Biopharma Inc

20.480

+0.900+4.60%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Theravance Biopharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

Theravance Biopharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 23 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 26.71.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Theravance Biopharma Inc's Score

Industry at a Glance

Industry Ranking

23 / 159

Overall Ranking

70 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Theravance Biopharma Inc Highlights

StrengthsRisks

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development and commercialization of medicines for the specialty respiratory and neurologic diseases. The Company operates through a single segment, namely, development and commercialization of human therapeutics. Its product, YUPELRI (revefenacin) inhalation solution, is a nebulized long-acting muscarinic antagonist used for the treatment of patients with chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in the lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Its Ampreloxetine, is a late-stage investigational norepinephrine reuptake inhibitor in development for the treatment of symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 25.39% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 64.38M.

Overvalued

The company’s latest PE is 35.32, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 49.89M shares, decreasing 7.38% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 532.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.59.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

26.714

Target Price

+36.44%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Theravance Biopharma Inc is 8.30, ranking 77 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 19.99M, representing a year-over-year increase of 18.51%, while its net profit experienced a year-over-year increase of 128.47%.

Score

Industry at a Glance

Previous score

8.30

Change



Financials

9.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.42

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.50

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Theravance Biopharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Theravance Biopharma Inc is 7.25, ranking 86 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 35.32, which is 70.86% below the recent high of 60.35 and 151.64% above the recent low of -18.24.

Score

Industry at a Glance

Previous score

7.25

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 23/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Theravance Biopharma Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 27.00, with a high of 42.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

26.714

Target Price

+36.44%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

Theravance Biopharma Inc

TBPH

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Theravance Biopharma Inc is 9.25, ranking 31 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 21.54 and the support level at 18.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.34

Change

1.91

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.066

Neutral

RSI(14)

59.364

Neutral

STOCH(KDJ)(9,3,3)

74.290

Buy

ATR(14)

0.824

Low Volatility

CCI(14)

22.613

Neutral

Williams %R

24.444

Buy

TRIX(12,20)

0.179

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

19.994

Buy

MA10

19.669

Buy

MA20

19.910

Buy

MA50

19.104

Buy

MA100

17.079

Buy

MA200

14.169

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Theravance Biopharma Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 98.45%, representing a quarter-over-quarter increase of 5.12%. The largest institutional shareholder is The Vanguard, holding a total of 2.37M shares, representing 4.67% of shares outstanding, with 12.28% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Madison Avenue Partners LP

9.51M

Weiss Asset Management

7.46M

Newtyn Management, LLC

4.95M

BlackRock Institutional Trust Company, N.A.

3.23M

-1.92%

Irenic Capital Management LP

2.76M

The Vanguard Group, Inc.

Star Investors

2.21M

+2.51%

Park West Asset Management LLC

1.28M

-28.63%

Winningham (Rick E)

1.23M

-5.16%

D. E. Shaw & Co., L.P.

1.21M

+20.72%

Oasis Management Company Ltd.

1.12M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Theravance Biopharma Inc is 6.12, ranking 60 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Theravance Biopharma Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.